| |
-Vaginal Culture
-Vaginal Culture Neisseria Gonorrhoeae Only
-Vaginal Trich Smear
-Vaginitis DNA Probe (VGDNA)
-Valproic Acid (VALP)
-Valproic Acid, Free (FRVA)
-Vancomycin, Peak (VANP)
-Vancomycin, Random (VANC)
-Vancomycin, Trough (VANT)
-Vanillylmandelic Acid, 24-Hour Urine (VMAU)
-VAP Cholesterol (VAPCH)
-Varicella-Zoster DFA (VZDFA)
-Varicella-Zoster IgG Antibody, Immune Status (HZVA)
-Varicella-Zoster Screen
-Varicella-Zoster Virus IgM Antibody (HZVM)
-Varicella-Zoster Virus, PCR, Cerebrospinal Fluid (VZVPR)
-Varicella-Zoster, Culture
-Vasoactive Intestinal Polypeptide (VIP)
-VBG
-VDRL, Cerebrospinal Fluid (VDRL)
-Venom Allergen Profile
-Venous Blood Gas
-Ventricular Fluid Culture
-Ventricular Tap Cytology
-Verapamil (VERP)
-Very Long Chain Fatty Acids
-VIII Antigen
-VIP
-Viral Culture, Bronchial Wash
-Viral Culture, Nasopharyngeal
-Viral Culture, Pulmonary Biopsy
-Viral Culture, Throat Swab
-Virtual HIV-1 Genotype
-Virtual Phenotype Profile (PTYPE)
-Viscosity, Fluid (FVIS)
-Viscosity, Serum (VISC)
-Vitamin A (VITAB)
-Vitamin B1 (VTB1)
-Vitamin B12, Serum (VB12)
-Vitamin B6 (VTB6)
-Vitamin C (VITC)
-Vitamin D, 1,25-Dihydroxy (VDDI)
-Vitamin D, 25-Hydroxy (VD2D3)
-Vitamin E (VITAE)
-Vitamin K (VITK)
-Vivactyl®
-VMA, 24-Hour Urine
-Volatile Screen (VOSC)
-von Willebrand Disease Profile
-von Willebrand Factor
|
|
|
|
Print |
| Vaginal Culture |
| |
| See Culture, Genital |
Print |
| Vaginal Culture Neisseria Gonorrhoeae Only |
| |
| See Culture, Neisseria Gonorrhoeae (GC Screen) |
Print |
| Vaginal Trich Smear |
| |
| See Trichomonas vaginalis Preparation |
Print |
| Vaginitis DNA Probe |
| |
| Includes: |
• Determine presence of: • Candida species • Gardnerella vaginalis (bacterial vaginosis) • Trichomonas vaginalis |
| |
| CPT: |
87800 |
| |
| Alternate Name: |
AFFIRM VPIII®; Cervical DNA Probe; DNA Probe for Candida species; DNA Probe for Gardnerella vaginalis; DNA Probe for Trichomonas vaginalis |
| |
| Methodology: |
DNA Probe, Affirm VPIII |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Container: |
AFFIRM VPIII ambient temperature transport system |
| |
| Collection: |
Follow package instructions on collection kit: • Label the sample collection tube (SCT) with the patient identification information. • Remove Ambient temperature transport regent (ATTS) dropper from package in collection kit, break ampule in reagent dropper and dispense liquid into tube provided in collection kit. • Place patient in position for pelvic examination, insert an unlubricated speculum (without jelly or water) into the vagina to permit visualization of posterior vaginal fornix OR If using a lubricated speculum, partially insert into vagina and collect specimen from above speculum. • Remove swab from packaging in collection kit. • Using swab from collection kit, obtain a sample from the posterior vaginal fornix; twist or roll the swab against the vaginal wall 2-3 times, ensuring the entire circumference of the swab has touched the vaginal wall. Swab the lateral vaginal wall while removing the swab. • IMMEDIATELY place swab into tube (SCT) and break swab at score line. • Close cap firmly and transport to the laboratory within 72 hours. |
| |
| Special Instructions and/or Comments: |
DO NOT predispense ATTS reagent. The ATTS reagent is toxic and flammable, avoid inhalation and skin contact when dispensing reagent. |
| |
| Reference Range: |
Negative for Candida species, Gardnerella vaginalis and Trichomonas vaginalis |
| |
| Clinical Utility: |
| Detection of causative agents of vaginitis and bacterial vaginosis: Trichomonas vaginalis, Candida species, and Gardenella vaginalis. |
| |
Print |
| Valproic Acid |
| |
| CPT: |
80164 |
| |
| Alternate Name: |
Depakene®; Sodium Valproate, Depakote |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top tube, or serum separator |
| |
| Reference Range: |
| Therapeutic: 50-100 .µg/mL |
| |
| Critical Values: |
| >200 .µg/mL |
| |
| Clinical Utility: |
| Useful for monitoring therapy and assessing toxicity. |
| |
Print |
| Valproic Acid, Free |
| |
| Includes: |
Valproic Acid, Free |
| |
| CPT: |
80164 |
| |
| Alternate Name: |
Depakene®, Free; Depakote®, Free |
| |
| Methodology: |
Ultrafiltration, Immunoassay |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum or plasma |
| |
| Container: |
Red top tube, no serum separator or Green top, Lithium Heparin |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Free: • Therapeutic..................4-15 µg/mL • Toxic...........................>15 µg/mL |
| |
| Clinical Utility: |
| The Valproic acid that circulates in blood is 85-90 % protein bound under normal circumstances. Since neurologic activity and toxicity of valproic acid are directly related to the unbound fraction of the drug, measurement of the free or unbound drug may be necessary where altered protein binding is possible, such as in hypoalbuminemia, pregnancy, renal or hepatic failure, the elderly or use of concomitant drug therapy. |
| |
Print |
| Vancomycin, Peak |
| |
| CPT: |
80202 |
| |
| Alternate Name: |
Vancocin® |
| |
| Methodology: |
Immunoassay |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top or SST tube |
| |
| Collection: |
• Peak: Collect 1 hour after completion of a 60-minute I.V. infusion. • Trough: Collect immediately prior to next dose. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • If delay in testing, centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Trough: Normal Therapeutic range is 10-20 µg/ml. For the management of central nervous system infections, endocarditis, or health care associated pneumonia, trough levels of 15-20 ug/ml are suggested. Peak: Therapeutic: 30-40 ug/ml |
| |
| Critical Values: |
| >40µg/mL |
| |
| Clinical Utility: |
| Useful for assessing adequate clearance, monitoring adequate blood concentrations during therapy and assessing toxicity. |
| |
Print |
| Vancomycin, Trough |
| |
| CPT: |
80202 |
| |
| Alternate Name: |
Vancocin® |
| |
| Methodology: |
Immunoassay |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top or SST tube |
| |
| Collection: |
• Peak: Collect 1 hour after completion of a 60-minute I.V. infusion. • Trough: Collect immediately prior to next dose. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • If delay in testing, centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Trough: • Normal Therapeutic range is 10-20 µg/ml. • For the management of central nervous system infections, endocarditis, or health care associated pneumonia, trough levels of 15-20 ug/ml are suggested. Peak: Therapeutic: 30-40 ug/ml |
| |
| Critical Values: |
| >40µg/mL |
| |
| Clinical Utility: |
Useful for assessing adequate clearance, monitoring adequate blood concentrations during therapy and assessing toxicity. |
| |
Print |
| Vancomycin, Random |
| |
| CPT: |
80202 |
| |
| Alternate Name: |
Vancocin® |
| |
| Methodology: |
Immunoassay |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Container: |
Red top or SST tube |
| |
| Collection: |
• Peak: Collect 1 hour after completion of a 60-minute I.V. infusion. • Trough: Collect immediately prior to next dose. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • If delay in testing, centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Trough: Normal Therapeutic range is 10-20 µg/ml. For the management of central nervous system infections, endocarditis, or health care associated pneumonia, trough levels of 15-20 ug/ml are suggested. Peak: Therapeutic: 30-40 ug/ml |
| |
| Critical Values: |
| >40µg/mL |
| |
| Clinical Utility: |
| Useful for assessing adequate clearance, monitoring adequate blood concentrations during therapy and assessing toxicity. |
| |
Print |
| Vanillylmandelic Acid, 24-Hour Urine |
| |
| Includes: |
• Volume Measurement • Collection Period • Vanillylmandelic Acid, Urine |
| |
| CPT: |
81050,84585 |
| |
| Alternate Name: |
VMA, 24-Hour Urine |
| |
| Methodology: |
Liquid Chromatography / Tandem Mass Spectrometry (LC-MS/MS) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
25 mL aliquot of a well mixed 24-hour urine collection. |
| |
| Container: |
• 24 hour plastic urine container • Add 15 mL of 50% acetic acid at beginning of collection |
| |
| Collection: |
• Instruct the patient to void at the beginning of collection period and discard the specimen • Collect all urine including the final specimen voided at the end of the collection period. • Refrigerate during collection • Container must be labeled with the patient’s name |
| |
| Special Instructions and/or Comments: |
• Instruct patient not to void directly into container. • Transport to the laboratory promptly |
| |
| Reference Range: |
| Adults: <8.0 mg/24 hours |
| |
| Clinical Utility: |
| Useful for screening for cathecholamine-secreting tumors in children when accompanied by homovanillic acid (HVA). Supporting a diagnosis of neuroblastoma. Monitoring neuroblastoma treatment. In the past, this test has been used to screen for pheochrome-cytoma. However, VMA is not the analyte of choice to rule out a diagnosis of pheochromocytoma . Recommended tests for this purpose are Metanephrines, Fractionated, Free, Plasma (PLMET), Metanephrines, Fractionated, 24-Hour, Urine (FMET), and/or Catecholemines, 24-Hour Urine (UCAT). |
| |
Print |
| Varicella-Zoster, Culture |
| |
| See Culture, Viral, General |
Print |
| Varicella-Zoster DFA |
| |
| CPT: |
87290 |
| |
| Alternate Name: |
Herpes Zoster |
| |
| Methodology: |
Direct Fluorescent Antibody Test |
| |
| Testing Schedule: |
7 days a week, 0700-1530 |
| |
| Report Available: |
1 day |
| |
| Special Instructions and/or Comments: |
• Slides are prepared by physician and should be transported to the laboratory promptly. |
| |
| Reference Range: |
| Direct FA negative for Varicella Zoster virus. |
| |
| Clinical Utility: |
| Varicella –Zoster virus, a member if the Herpes group, causes chicken pox (Varicella) .After an attack of chickenpox, the virus lies dormant in the nerve tissue. It can reactivate and reappear later in life in the form of shingles (Herpes Zoster), a skin disease with painful rashes, blisters, and sores similar to chickenpox. |
| |
Print |
| Varicella-Zoster IgG Antibody, Immune Status |
| |
| CPT: |
86787 |
| |
| Alternate Name: |
Chickenpox Immune Status; Herpes Zoster Antibody; Herpes Zoster Screen for Immune Status;Shingles Screen for Immune Status; Varicella-Zoster Screen; VZV Screen |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Reference Range: |
See table Varicella-Zoster IgG Antibody Screen| ELISA Antibody | Index Interpretation | Comment | | <=0.90 | Negative | Indicates no detectable IgG antibody to Varicella (herpes) Zoster virus. Patient is not immune and therefore susceptible to primary infection. If primary infection is suspected, specimens obtained within days after onset of symptoms may not contain detectable IgG antibodies, and second specimen should be obtained in 14-21 days. | | 0.91-1.09 | Equivocal | IgG antibody levels to Varicella (herpes) Zoster virus may not equate with immunity. Suggest a new specimen be submitted for testing | | >=1.10 | Positive | Indicates presence of detectable IgG antibody to Varicella (herpes) Zoster virus. Patient is immune. Results suggest past infection or vaccination. Immunity to exogenous reinfection is lifelong, so second attacks of disease are virtually unknown. However, recurrence of virus may occur in the form of zoster. |
|
| |
| Clinical Utility: |
| Diagnose Varicella Zoster Virus (VZV) infection; determine adult susceptibility to infection. |
| |
Print |
| VAP Cholesterol |
| |
| Includes: |
• Total LDL • Total HDL • Total VLDL • Total Cholesterol • Triglyceride • Total Non-HDL Cholesterol(LDL + VLDL) • Lp(a) Cholesterol • Remnant Lipoproteins, LDL subclasses • HDL subclasses, VLDL subclasses • LDL Pattern size |
| |
| CPT: |
83701,84478 |
| |
| Methodology: |
Ultracentrifugation, Spectrophotometry |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL Serum |
| |
| Container: |
2 Gold Top (Serum Separator) Tubes |
| |
| Special Instructions and/or Comments: |
• Refrigerate • Fasting Specimen Required |
| |
| Reference Range: |
| Accompanies report |
| |
| Clinical Utility: |
| Useful to identify cholesterol abnormalties. |
| |
Print |
| Varicella-Zoster Screen |
| |
| See Varicella-Zoster IgG Antibody, Immune Status |
Print |
| Varicella-Zoster Virus IgM Antibody |
| |
| CPT: |
86787 |
| |
| Methodology: |
Enzyme Immunoassay (EIA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| <0.91 titer |
| |
| Critical Values: |
| Positive results are reported to the appropriate State Department of Health. |
| |
| Clinical Utility: |
| To aid in the determination of current or recent Varicella-Zoster Virus (Chickenpox) infection. |
| |
Print |
| Varicella-Zoster Virus, PCR, Cerebrospinal Fluid |
| |
| CPT: |
87799 |
| |
| Alternate Name: |
VZV, PCR, CSF |
| |
| Methodology: |
Rapid Polymerase Chain Reaction (RT-PCR) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL frozen cerebrospinal fluid |
| |
| Container: |
Sterile conical tube *Each test ordered must have a separate tube of frozen CSF* |
| |
| Special Instructions and/or Comments: |
• Aliquot specimen into 2 plastic vials and freeze. Once frozen, transport specimen submerged in dry ice. • Specimen must be frozen within 4 hours of collection |
| |
| Reference Range: |
| <500 copies/mL |
| |
| Clinical Utility: |
| Quantitates Varicella-zoster virus DNA down to 500 copies/mL to monitor viral load and therapeutic efficacy, primarily in immunocompromised patients. |
| |
Print |
| Vasoactive Intestinal Polypeptide |
| |
| CPT: |
84586 |
| |
| Alternate Name: |
VIP |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL plasma |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Collection: |
8 hour fasting required. NOTE: This test should not be done on a patient who recently received radioactive material. |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| < 75.0 pg/mL |
| |
| Clinical Utility: |
| Useful for, detection of VIPoma in patients with chronic diarrheal diseases. |
| |
Print |
| VBG |
| |
| See Blood Gas, Venous |
Print |
| VDRL, Cerebrospinal Fluid |
| |
| Includes: |
• VDRL, Qualitative Screen • Reactive screens are titered and reported quantitatively |
| |
| CPT: |
86592, Reflexed when appropriate: 86593 |
| |
| Alternate Name: |
Cerebrospinal Fluid VDRL; CSF VDRL; Serologic Test for Syphilis, CSF; Spinal Fluid VDRL |
| |
| Methodology: |
Flocculation |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.5 mL cerebrospinal fluid |
| |
| Container: |
Sterile conical tube |
| |
| Special Instructions and/or Comments: |
| Serum is NOT acceptable for analysis, see RPR listing. |
| |
| Reference Range: |
| Nonreactive (NR) |
| |
| Clinical Utility: |
| Test for syphilis, neurosyphilis. Although false positives in the VDRL test are generally restricted to serum and are not usually found in VDRL CSF, the possibility of false positives must always be considered. |
| |
Print |
| Venom Allergen Profile |
| |
| See Allergen Profile, Venom |
Print |
| Venous Blood Gas |
| |
| See Blood Gas, Venous |
Print |
| Ventricular Fluid Culture |
| |
| See Culture, Cerebrospinal Fluid |
Print |
| Ventricular Tap Cytology |
| |
| See Cytopathology, Cerebrospinal Fluid |
Print |
| Verapamil |
| |
| Includes: |
• Verapamil • Norverapamil Metabolite |
| |
| CPT: |
80299 |
| |
| Alternate Name: |
Calan®; Isoptin® |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL serum |
| |
| Container: |
Red top tube (large 10mL), no serum separator |
| |
| Collection: |
Collect 1-2 hours after last dose. |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Verapamil: • Therapeutic: 100-600 ng/mL Norverapamil: • Therapeutic: 100-400 ng/mL |
| |
| Clinical Utility: |
| Useful for, assessing achievement of optimal therapeutic levels. |
| |
Print |
| Very Long Chain Fatty Acids |
| |
| See Fatty Acid Profile, Peroxismal (C22-C26) |
Print |
| VIII Antigen |
| |
| See Factor VIII Antigen |
Print |
| VIP |
| |
| See Vasoactive Intestinal Polypeptide |
Print |
| Viral Culture, Bronchial Wash |
| |
| See Culture, Viral, Respiratory |
Print |
| Viral Culture, Nasopharyngeal |
| |
| See Culture, Viral, Respiratory |
Print |
| Viral Culture, Pulmonary Biopsy |
| |
| See Culture, Viral, Respiratory |
Print |
| Viral Culture, Throat Swab |
| |
| See Culture, Viral, Respiratory |
Print |
| Virtual HIV-1 Genotype |
| |
| See Virtual Phenotype Profile |
Print |
| Virtual Phenotype Profile |
| |
| Includes: |
• HIV-1 Viral Load, PCR, Ultrasenstitive • Reflexed when appropriate: • Additional HIV-1 Viral Load quantitation when ultrasensitive values are >100,000 copies/mL • HIV-1 Genotype when HIV-1 Viral Load is >1,000 copies/mL • Virtual Phenotype when HIV-1 Viral Load is >1,000 copies/mL |
| |
| CPT: |
87536 Reflexed when appropriate: 87536, 87901, 0023T |
| |
| Alternate Name: |
Virtual HIV-1 Genotype |
| |
| Methodology: |
• Reverse Transcription Polymerase Chain Reaction (RT-PCR) COBAS Amplicor Monitor Test, Version 1.5 • Rapid Polymerase Chain Reaction (RT-PCR) with DNA Sequencing |
| |
| Testing Schedule: |
Routine, Monday-Friday |
| |
| Report Available: |
10-14 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
8 mL plasma |
| |
| Container: |
4 White top (EDTA) plastic tubes |
| |
| Special Instructions and/or Comments: |
• DO NOT submit heparinized specimen. • Transport whole blood at 2-25C • Must be processed within 6 hours of collection. • Centrifuge specimen. DO NOT aliquot. Freeze 2 original tubes and refrigerate the 2 remaining tubes. Once frozen, transport specimen submerged in dry ice. • A HIV-1 Viral Load of >1,000 copies/mL is required for the specimen to be valid for both HIV- 1 Genotype and Virtual Phenotype testing. NOTE: No HIV-1 Genotype or Virtual Phenotype results will be reported on specimens with <1,000 copies/mL. |
| |
| Reference Range: |
| See report. |
| |
| Clinical Utility: |
• The use of resistance testing is recommended. • Whenever treatment is to be changed • In HIV positive pregnancies • When treatment is initiated Phenotyping can predict HIV-1 drug resistance, guide selection of effective antiretroviral drugs, and monitor transmission of drug- resistant HIV-1. |
| |
Print |
| Viscosity, Fluid |
| |
| CPT: |
85810 |
| |
| Alternate Name: |
Fluid Viscosity; Synovial Fluid, Viscosity |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL synovial fluid |
| |
| Container: |
Sterile tube or red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| High |
| |
| Clinical Utility: |
| Used in the evaluation of inflammatory and infectious disorders. |
| |
Print |
| Viscosity, Serum |
| |
| CPT: |
85810 |
| |
| Alternate Name: |
Serum Viscosity |
| |
| Testing Schedule: |
Routine, daily |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Reference Range: |
| 1.1 - 20 mPa.S |
| |
| Clinical Utility: |
| Evaluate hyperviscosity syndrome associated withmonoclonal gammopathy states (myeloma, macroglobulinemia of Waldenstrom, and otherdysproteinemias), including occasional cases of rheumatoid arthritis, SLE, systemic lupus erythematosus, hyperfibrinogenemia. |
| |
Print |
| Vitamin A |
| |
| CPT: |
84590 |
| |
| Alternate Name: |
Retinol, Serum |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Collection: |
• Overnight 12-14 hour fast required. • Infants draw prior to next feeding |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Protect from light by wrapping the entire aliquot tube with aluminum foil or use amber aliquot vial. |
| |
| Reference Range: |
Retinol: • 0-6 years old:....................113-647 ug/L • 7-12 years old...................128-812 ug/L • 13-17 years old:................144-977 ug/L • > 18 years old..................325-780 ug/L |
| |
| Clinical Utility: |
| Useful for, diagnosing vitamin A deficiency and toxicity. |
| |
Print |
| Vitamin B1 |
| |
| CPT: |
84425 |
| |
| Alternate Name: |
Thiamine |
| |
| Methodology: |
Flourimetry |
| |
| Testing Schedule: |
Routine, 2 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL plasma |
| |
| Container: |
2 Lavender top (EDTA) tube |
| |
| Collection: |
Draw 2 tubes to prevent a quantity not sufficient result. 3 mLs of plasma is the minimum requirement. |
| |
| Special Instructions and/or Comments: |
• Must be processed and frozen immediately • Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Protect from light by wrapping the entire aliquot tube with aluminum foil or use amber aliquot vial |
| |
| Reference Range: |
| 4.5 - 15.1 nmol/L |
| |
| Clinical Utility: |
| Assessment of thiamin deficiency. |
| |
Print |
| Vitamin B6 |
| |
| CPT: |
84207 |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL plasma |
| |
| Container: |
Green top (sodium heparin) tube |
| |
| Collection: |
• No alcohol or vitamin consumption 24 hours prior to collection • Overnight 12-14 hour fast is required • Infants: Draw prior to next feeding. |
| |
| Special Instructions and/or Comments: |
• Must be processed and frozen immediately. • Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Protect from light by wrapping the entire aliquot tube with aluminum foil. |
| |
| Reference Range: |
| 5-50 µg/mL |
| |
| Clinical Utility: |
| Useful for, determining vitamin B(6) status, including in persons who present with progressive nerve compression disorders, such as carpal tunnel and tarsal tunnel syndromes. Determining the overall success of a vitamin B(6) supplementation program. Diagnosis and evaluation of hypophosphatasia |
| |
Print |
| Vitamin B12, Serum |
| |
| CPT: |
82607 |
| |
| Alternate Name: |
B12; Cobalamin, True; Cyanocobalamin |
| |
| Methodology: |
Direct Chemiluminescence |
| |
| Testing Schedule: |
Routine; STAT testing available 0600-2100 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
• Testing must be performed within 8 hours of collection. • If delay in transport, specimen, transfer to plastic aliquot tube and refrigerate tube in the upright position. Specimen should remain capped until time of testing. |
| |
| Reference Range: |
| >211 pg/mL |
| |
| Clinical Utility: |
| Assist in the diagnosis of hematologic and/or neurologic states. |
| |
Print |
| Vitamin C |
| |
| CPT: |
82180 |
| |
| Alternate Name: |
Ascorbic Acid |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL plasma |
| |
| Container: |
Green top (sodium heparin) tube |
| |
| Collection: |
• Overnight 12-14 hour fast required, water can be taken as needed. • Infants: Draw prior to next feeding |
| |
| Special Instructions and/or Comments: |
• Keep specimen cold and centrifuge within 4 hours of collection • Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Protect from light by wrapping the entire aliquot tube with aluminum foil. |
| |
| Reference Range: |
| 0.6-2.0 mg/dL |
| |
| Clinical Utility: |
Useful for: • The diagnosis of vitamin C deficiency. • As an aid to deter of excessive intake. |
| |
Print |
| Vitamin D, 1,25-Dihydroxy |
| |
| CPT: |
82652 |
| |
| Methodology: |
Extraction/Liquid Chromatography-Tandem Mass Spectrometry LC-MS/MS |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2.0 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Fasting patient preferred. (4 hours preferred but not required) |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Males: 24-86 pg/mL (<16 y) 18-64 pg/mL (>=16 y) Females: 24-86 pg/mL (<16 y) 18-78 pg/mL (>=16 y) |
| |
| Clinical Utility: |
| Useful for the differential diagnosis of hypercalcemia. 1,25 dihydroxy vitamin D levels may be needed along with Vitamin D, 25-Hydroxy (VD2D3) to adequately assess vitamin D status. May be useful in the investigation of some patients with clinical evidence of vitamin D deficiency (e.g., vitamin D-dependent rickets due to hereditary deficiency of renal 1-alphahydroxylase or end-organ resistance to 1,25-dihydroxy vitamin D). |
| |
Print |
| Vitamin D, 25-Hydroxy |
| |
| CPT: |
82306 |
| |
| Alternate Name: |
Calcifediol, Calcidiol |
| |
| Methodology: |
LC-MS/MS Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS |
| |
| Testing Schedule: |
Daily, M-F |
| |
| Report Available: |
2-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Fasting patient preferred. |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and refrigerate. |
| |
| Reference Range: |
• <10 ng/mL (severe deficiency) • 10-24 ng/mL (mild to moderate deficiency) • 25-80 ng/mL (optimum levels) • >80 ng/mL (toxicity possible) |
| |
| Clinical Utility: |
| Useful for, the diagnosis of vitamin D deficiency. Differential diagnosis of causes of rickets and Osteomalacia Monitoring vitamin D placement Therapy Diagnosis of hypervitaminosis D. |
| |
Print |
| Vitamin E |
| |
| CPT: |
84446 |
| |
| Alternate Name: |
Alpha Tocopherol |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC), Specific quantitation of alpha tocopherol |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL |
| |
| Container: |
Red top tube, no serum separator |
| |
| Collection: |
• Overnight fast (12-14 hours) required. • Infants draw prior to next feeding |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Protect from light by wrapping the entire aliquot tube with aluminum foil or use amber aliquot tube |
| |
| Reference Range: |
0-17 years:.......................3.8-18.4 mg/L > 18 years:........................5.5-17.0 mg/L Significant deficiency:......< 3.0 mg/L Significant excess:............ > 40 mg/L |
| |
| Clinical Utility: |
| Useful for the diagnosis of (or evaluation of) individuals with motor and sensory neuropathies. Monitoring vitamin E status of premature infants requiring oxygenation. Evaluation of persons with intestinal malabsorption of lipids. |
| |
Print |
| Vitamin K |
| |
| CPT: |
84597 |
| |
| Methodology: |
HPLC |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL (minimum 2 mL) heparinized plasma |
| |
| Container: |
Green top (sodium heparin) tube |
| |
| Collection: |
Overnight fast is preferred |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice • Protect from light by wrapping the entire aliquot tube with aluminum foil or using amber aliquot tubes. |
| |
| Reference Range: |
| 80-1160 pg/mL |
| |
| Clinical Utility: |
| Useful for determining vitamin K status |
| |
Print |
| Vivactyl® |
| |
| See Protriptyline |
Print |
| VMA, 24-Hour Urine |
| |
| See Vanillylmandelic Acid, 24-Hour Urine |
Print |
| Volatile Screen |
| |
| Includes: |
• Identification and quantitation of: • Ethanol • Methanol • Isopropanol • Acetone |
| |
| CPT: |
84600 |
| |
| Methodology: |
Gas Chromatography (GC) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL whole blood OR serum |
| |
| Container: |
Gray top (sodium fluoride) tube OR red top tube, no serum separator |
| |
| Collection: |
• Prepare skin with Betadine® or Zephiran®. • DO NOT use an alcohol swab. |
| |
| Special Instructions and/or Comments: |
• DO NOT centrifuge, aliquot or freeze. • Must remain as whole blood in original tube. • Refrigerate only. |
| |
| Reference Range: |
| Negative |
| |
| Critical Values: |
Toxic: • Acetone: >20 mg/dL or 0.02% • Ethanol: >200 mg/dL or 0.20% • Isopropanol: >20 mg/dL or 0.02% • Methanol: >10 mg/dL or 0.01% |
| |
| Clinical Utility: |
| Useful for detecting and assessing possible toxicity from ingestion of ethanol, methanol, acetone, or isopropanol. |
| |
Print |
| von Willebrand Disease Profile |
| |
| See von Willebrand Profile, Comprehensive |
Print |
| von Willebrand Factor |
| |
| See Ristocetin Cofactor |
Print |
| von Willebrand Multimers |
| |
| CPT: |
85247 |
| |
| Methodology: |
Western Blot (WB) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL plasma, split equally into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Testing is contraindicated for patients on Heparin or Coumadin therapy. • Immediately centrifuge the specimens at 1500-1700 X G for 10 minutes. Avoiding the buffy coat, carefully remove the plasma from the cells using a plastic aliquot pipette. Aliquot the plasma into the required number of plastic aliquot tubes and label with “citrated plasma” labels. • Freeze the aliquoted specimens at –40 to –60°C. Once frozen, transport the specimens submerged in dry ice. Causes for rejection: • Extended transport time to laboratory • Clotted specimens • Hemolyzed specimens • Blue top sodium citrate tubes insufficiently filled • Aliquots not received frozen on dry ice • Frozen aliquots not clearly identified as “citrated plasma” |
| |
| Reference Range: |
| See report. |
| |
| Clinical Utility: |
| Useful when type 2 von Willebrand disease is suspected and to further categorize disease. |
| |
Print |
| von Willebrand Profile, Comprehensive |
| |
| Includes: |
• Partial Thromboplastin Time, Activated (APTT) • Factor VIII Activity • Factor VIII Antigen • Ristocetin Cofactor • Ristocetin Aggregation • Interpretation |
| |
| CPT: |
85730, 85240, 85246, 85245, 85576 |
| |
| Alternate Name: |
von Willebrand Disease Profile |
| |
| Methodology: |
See individual test listings. |
| |
| Testing Schedule: |
NOTE: Testing is performed by appointment only due to the handling of the ristocetin aggregation. This procedure must be scheduled in advance. |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL plasma AND 10 mL whole blood |
| |
| Container: |
6 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Transport all tubes at room temperature and deliver immediately to the testing department. • No more than 2 hours can elapse from the time of collect to time of receipt in the laboratory. • DO NOT chill; platelets are activated at low temperatures. • DO NOT centrifuge or aliquot; must remain as whole blood in original tubes. Causes for rejection: • Extended transport time to laboratory • Clotted specimens • Hemolyzed specimens • Blue top sodium citrate tubes insufficiently filled |
| |
| Reference Range: |
| See individual test listings. |
| |
| Clinical Utility: |
| See individual test listings. |
| |
Print |
| VRE Screening Culture |
| |
| See Culture, Vancomycin-Resistant Enterococci Screen |
Print |
| vW Factor Assay |
| |
| See Ristocetin Cofactor |
Print |
| vWF Antigen |
| |
| See Factor VIII Antigen |
Print |
| VZV Screen |
| |
| See Varicella-Zoster IgG Antibody,Immune Status |
|